Compare Stocks → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GRPHNASDAQ:IKNANASDAQ:INMBNASDAQ:SRNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRPHGraphite Bio$3.18-2.8%$19.62$2.01▼$4.26$185.20M0.2282,405 shs328,300 shsIKNAIkena Oncology$1.42+2.2%$1.43$1.02▼$7.64$68.53M0.32407,178 shs155,449 shsINMBINmune Bio$11.75+1.0%$12.14$5.87▼$14.74$211.74M1.9978,741 shs96,381 shsSRNESorrento Therapeutics$0.01$0.03$0.16▼$3.09$3.78M1.9552.69 million shs210,550 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRPHGraphite Bio0.00%-85.71%-85.62%-82.66%-81.31%IKNAIkena Oncology+2.16%-5.33%-5.96%-27.92%-60.56%INMBINmune Bio+1.03%-1.43%-2.97%+4.35%+74.07%SRNESorrento Therapeutics-11.11%-60.00%-71.43%-93.52%-97.65%Top Project Outperforms BTC in 2023… (Ad)According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRPHGraphite BioN/AN/AN/AN/AN/AN/AN/AN/AIKNAIkena Oncology2.8136 of 5 stars3.53.00.00.02.51.71.3INMBINmune Bio0.8381 of 5 stars3.50.00.00.01.81.70.0SRNESorrento TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRPHGraphite BioN/AN/AN/AN/AIKNAIkena Oncology3.00Buy$9.50569.01% UpsideINMBINmune Bio3.00Buy$16.0036.17% UpsideSRNESorrento TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest GRPH, SRNE, IKNA, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2024IKNAIkena OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/12/2024IKNAIkena OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.001/19/2024IKNAIkena OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.001/19/2024IKNAIkena OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRPHGraphite BioN/AN/AN/AN/A$3.15 per shareN/AIKNAIkena Oncology$9.16M7.48N/AN/A$3.52 per share0.40INMBINmune Bio$370K572.26N/AN/A$3.35 per share3.51SRNESorrento Therapeutics$60.32M0.06N/AN/A$0.26 per share0.03Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRPHGraphite Bio-$124.65M-$2.23N/AN/AN/AN/A-33.12%-27.96%N/AIKNAIkena Oncology-$68.17M-$1.64N/AN/AN/A-327.46%-44.21%-37.27%5/20/2024 (Estimated)INMBINmune Bio-$27.30M-$1.52N/A∞N/A-12,246.88%-52.26%-38.08%N/ASRNESorrento Therapeutics-$428.33MN/A0.00N/AN/A-818.22%-282.82%-57.64%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRPHGraphite BioN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/ALatest GRPH, SRNE, IKNA, and INMB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/15/2024GRPHGraphite Bio$7.2128.93%3/15/20243/18/20243/21/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRPHGraphite BioN/A39.2039.20IKNAIkena OncologyN/A12.5812.58INMBINmune Bio0.053.183.18SRNESorrento Therapeutics0.140.880.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRPHGraphite Bio54.32%IKNAIkena Oncology75.00%INMBINmune Bio12.72%SRNESorrento Therapeutics34.48%Insider OwnershipCompanyInsider OwnershipGRPHGraphite Bio38.40%IKNAIkena Oncology5.95%INMBINmune Bio36.10%SRNESorrento Therapeutics2.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGRPHGraphite Bio658.24 million35.87 millionNot OptionableIKNAIkena Oncology4348.26 million45.39 millionNot OptionableINMBINmune Bio1018.02 million11.52 millionOptionableSRNESorrento Therapeutics799471.88 million459.61 millionOptionableGRPH, SRNE, IKNA, and INMB HeadlinesSourceHeadlineSorrento Therapeutics (NASDAQ:SRNE) Now Covered by StockNews.comamericanbankingnews.com - March 28 at 2:24 AMSorrento Therapeutics Wins Appeal Over Covid Treatment Remarksnews.bloomberglaw.com - March 27 at 4:18 AMSorrento Therapeutics Wins Appeal Over Covid Treatment Remarksnews.bloomberglaw.com - March 27 at 4:18 AMSorrento Therapeutics (NASDAQ:SRNE) Share Price Crosses Below 200 Day Moving Average of $0.08americanbankingnews.com - March 20 at 5:52 AMSorrento Therapeutics (NASDAQ:SRNE) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - March 20 at 3:30 AMSorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)news.bloomberglaw.com - March 12 at 6:20 PMJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy Casewsj.com - March 12 at 6:20 PMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.tmcnet.com - February 27 at 9:57 AMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.businesswire.com - February 27 at 7:30 AMSorrento Therapeuticspharmaphorum.com - February 7 at 10:34 AM5 Sanders Cove, Sorrento WA 6020domain.com.au - January 18 at 9:02 AMSorrento Therapeutics, Inc. (0L85.L)finance.yahoo.com - January 9 at 10:46 AMSorrento WA 6020domain.com.au - December 29 at 3:42 PMSorrento Therapeutics Inc SRNEQmorningstar.com - November 5 at 10:27 AM29 Normanby Road Sorrento VIC 3943domain.com.au - October 15 at 5:35 PMSorrento, Italy - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - October 14 at 3:34 PM151 Seacrest Drive Sorrento WA 6020domain.com.au - October 10 at 9:09 PMSorrento holiday apartment accommodation with beach/lake nearby, internet access, balcony/terrace and air conholidaylettings.co.uk - October 9 at 7:15 PM9 Sunset Strip Sorrento VIC 3943domain.com.au - September 14 at 9:37 AMCourt rules Virpax CEO Anthony Mack breached his agreement with Sorrento Therapeuticsbizjournals.com - September 7 at 5:29 PM122 Campbell Street Sorrento QLD 4217domain.com.au - August 21 at 3:59 PMSorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bidfinance.yahoo.com - August 8 at 11:08 AMCheap Flights from Glasgow to Sorrentoskyscanner.net - August 3 at 1:31 PMCheap Flights from Edinburgh to Sorrentoskyscanner.net - July 29 at 11:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGraphite BioNASDAQ:GRPHGraphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.Ikena OncologyNASDAQ:IKNAIkena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.Sorrento TherapeuticsNASDAQ:SRNESorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.